Interventions to prevent sexually transmitted infections, including HIV infection

Clinical Infectious Diseases

Volumn 53, Issue SUPPL. 3, 2011, Pages

  Marrazzo, Jeanne M ^a   Cates, Willard ^b  

^a University of Seattle   (United States)

^b FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; BUFFER; C 31 G; CARRAGEENAN; CELLULOSE SULFATE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FLUCONAZOLE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HEPATITIS C VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INJECTABLE CONTRACEPTIVE AGENT; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; METRONIDAZOLE; MIFEPRISTONE; N 9; ORAL CONTRACEPTIVE AGENT; PRO 2000; RECOMBINANT CANARY POX VECTOR VACCINE; RECOMBINANT GLYCOPROTEIN 120 SUBUNIT VACCINE; SAVVY; SPERMICIDAL AGENT; TENOFOVIR; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CIRCUMCISION; CONDOM; DISEASE TRANSMISSION; GEL; HEALTH CARE POLICY; HEPATITIS C; HERPES SIMPLEX; HIGH RISK POPULATION; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INFECTION PREVENTION; INFECTION RISK; MALE HOMOSEXUAL; NEISSERIA GONORRHOEAE; PATIENT COUNSELING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TRICHOMONIASIS; VAGINA CANDIDIASIS; VIRUS LOAD;

ADOLESCENT; ADULT; AIDS VACCINES; ANTIVIRAL AGENTS; BEHAVIOR THERAPY; CHEMOPREVENTION; CHILD; CIRCUMCISION, MALE; CONDOMS, FEMALE; CONTACT TRACING; FEMALE; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRUS VACCINES; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; SEXUALLY TRANSMITTED DISEASES; YOUNG ADULT;

EID: 81055125472     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir695     Document Type: Review

References (124)

1. Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines, 2006. MMWR Recomm Rep 2006; 51:1-94.
2. UNAIDS report on the global HIV/AIDS epidemic 2010, 2010.
3. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA 2008; 300:520-9.
4. Hall HI, Geduld J, Boulos D, et al. Epidemiology of HIV in the United States and Canada: current status and ongoing challenges. J Acquir Immune Defic Syndr 2009; 51(Suppl 1):S13-20.
5. Brooks JT, Kaplan JE, Holmes KK, Benson C, Pau A, Masur H. HIVassociated opportunistic infections-going, going, but not gone: the continued need for prevention and treatment guidelines. Clin Infect Dis 2009; 48:609-11.
6. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance, 2009. Atlanta, GA: US Department of Health and Human Services, 2010.
7. Centers for Disease Control and Prevention. HIV/AIDS surveillance report, 2008. vol 19. Available at: http://www.cdc.gov/hiv/topics/surveillance/ resources/reports/. Published June 2010. Accessed 13 December 2010.
8. Centers for Disease Control and Prevention. Chlamydia screening among sexually active young female enrollees of health plans-United States, 2000-2007. MMWR Morb Mortal Wkly Rep 2009; 58:362-5.
9. Centers for Disease Control and Prevention. Primary and secondary syphilis-Jefferson county, Alabama, 2002-2007. MMWR Morb Mortal Wkly Rep 2009; 58:463-7.
10. Giraudon I, Ruf M, Maguire H, et al. Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002-2006: is this an outbreak? Sex Transm Infect 2008; 84:111-5. (Pubitemid 351497921)
11. van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009; 136:1609-17.
12. van de Laar TJ, van der Bij AK, Prins M, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007; 196:230-8. (Pubitemid 47047462)
13. Kelly JA, Sikkema KJ, Holtgrave DR. Behavioral interventions for prevention of STDs and HIV infection at the community level. In: Holmes KK, Sparling PF, Stamm WE et al. eds. Sexually transmitted diseases. 4th ed. New York: McGraw Hill, 2008; 1849-56.
14. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1-24.
15. US Food and Drug Administration. Gardasil. Product approval information. Available at: http://www.fda.gov/cber/products/gardasil.htm Accessed 8 August 2011 .
16. Munoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009; 373:1949-57.
17. Petaja T, Keranen H, Karppa T, et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 2009; 44:33-40.
18. Giuliano AR, Lazcano-Ponce E, Villa LL, et al. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev 2008; 17:2036-43.
19. Cutts FT, Franceschi S, Goldie S, et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ 2007; 85:719-26. (Pubitemid 47416724)
20. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-70. (Pubitemid 46977438)
21. Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis-United States, 2007. MMWR Surveill Summ 2009; 58:1-27.
22. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55:1-33.
23. Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1-23.
24. Halliday J, Klenerman P, Barnes E. Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines 2011; 10:659-72.
25. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-65.
26. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, doubleblind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-71. (Pubitemid 44901996)
27. Fauci AS, Johnston MI, Dieffenbach CW, et al. HIV vaccine research: the way forward. Science 2008; 321:530-2.
28. Johnston MI, Fauci AS. An HIV vaccine-challenges and prospects. N Engl J Med 2008; 359:888-90.
29. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20.
30. Ness RB, Randall H, Richter HE, et al. Condom use and the risk of recurrent pelvic inflammatory disease, chronic pelvic pain, or infertility following an episode of pelvic inflammatory disease. Am J Public Health 2004; 94:1327-9. (Pubitemid 39006802)
31. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002; 1:CD003255
32. Gottlieb SL, Douglas JM Jr., Foster M, et al. Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling. J Infect Dis 2004. 190:1059-67. (Pubitemid 39186791)
33. Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001; 285:3100-6. (Pubitemid 32578207)
34. Nielson CM, Harris RB, Nyitray AG, Dunne EF, Stone KM, Giuliano AR. Consistent condom use is associated with lower prevalence of human papillomavirus infection in men. J Infect Dis 2010; 202:445-51.
35. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006; 354:2645-54.
36. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 2002; 29:725-35. (Pubitemid 35266418)
37. Hogewoning CJ, Bleeker MC, van den Brule AJ, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 2003; 107:811-6. (Pubitemid 37339736)
38. Bleeker MC, Hogewoning CJ, Voorhorst FJ, et al. Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. Int J Cancer 2003; 107:804-10. (Pubitemid 37339735)
39. Martin ET, Krantz E, Gottlieb SL, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med 2009; 169:1233-40.
40. Mehta SD, Moses S, Agot K, et al. Adult male circumcision does not reduce the risk of incident Neisseria gonorrhoeae, Chlamydia tracho-matis, or Trichomonas vaginalis infection: results from a randomized, controlled trial in Kenya. J Infect Dis 2009; 200:370-8.
41. Niccolai LM, Rowhani-Rahbar A, Jenkins H, Green S, Dunne DW. Condom effectiveness for prevention of Chlamydia trachomatis infection. Sex Transm Infect 2005; 81:323-5. (Pubitemid 41160738)
42. Hocking J, Fairley CK. Associations between condom use and rectal or urethral chlamydia infection in men. Sex Transm Dis 2006; 33:256-8.
43. Paz-Bailey G, Koumans EH, SternbergM, et al. The effect of correct and consistent condom use on chlamydial and gonococcal infection among urban adolescents. Arch Pediatr Adolesc Med 2005; 159:536-42. (Pubitemid 40973475)
44. Shafii T, Stovel K, Holmes K. Association between condom use at sexual debut and subsequent sexual trajectories: a longitudinal study using biomarkers. Am J Public Health 2007; 97:1090-5. (Pubitemid 351181933)
45. Martino SC, Elliott MN, Collins RL, Kanouse DE, Berry SH. Virginity pledges among the willing: delays in first intercourse and consistency of condom use. J Adolesc Health 2008; 43:341-8.
46. Rosenbaum JE. Patient teenagers? A comparison of the sexual behavior of virginity pledgers and matched nonpledgers. Pediatrics 2009; 123:e110-20.
47. Warner L, Newman DR, Austin HD, et al. Condom effectiveness for reducing transmission of gonorrhea and chlamydia: the importance of assessing partner infection status. Am J Epidemiol 2004; 159:242-51. (Pubitemid 38141653)
48. Gallo MF, Grimes DA, Lopez LM, Schulz KF. Nonlatex versus latex male condoms for contraception. Cochrane Database Syst Rev 2006. The Cochrane Library 2010; 12:1-102.
49. Nicholas LJ, Tredoux C, Daniels P. AIDS knowledge and attitudes towards homosexuals of black first-year university students: 1990-1992. Psychol Rep 1994; 75:819-23.
50. Vijayakumar G, Mabude Z, Smit J, Beksinska M, Lurie M. A review of female-condom effectiveness: patterns of use and impact on protected sex acts and STI incidence. Int J STD AIDS 2006; 17:652-9. (Pubitemid 44611145)
51. Minnis AM, Padian NS. Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: current evidence and future research directions. Sex Transm Infect 2005; 81:193-200. (Pubitemid 40835042)
52. Macaluso M, Blackwell R, Jamieson DJ, et al. Efficacy of the male latex condom and of the female polyurethane condom as barriers to semen during intercourse: a randomized clinical trial. Am J Epidemiol 2007; 166:88-96. (Pubitemid 47234293)
53. US Food and Drug Administration. CDRH Advisory Meeting Materials Archive. Obstetrics and Gynecology Devices Panel. 11 December 2008. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfAdvisory/details.cfm? mtg5708. Accessed 8 August 2011.
54. Gross M, Buchbinder SP, Holte S, Celum CL, Koblin BA, Douglas JM Jr. Use of Reality "female condoms" for anal sex by US men who have sex with men. HIVNET Vaccine Preparedness Study Protocol Team. Am J Public Health 1999; 89:1739-41. (Pubitemid 29508225)
55. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369:657-66.
56. Weiss HA, Halperin D, Bailey RC, Hayes RJ, Schmid G, Hankins CA. Male circumcision for HIV prevention: from evidence to action? AIDS 2008; 22:567-74. (Pubitemid 351640589)
57. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2:e298.
58. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369:643-56. (Pubitemid 46281312)
59. UNAIDS and World Health Organization. New data on male circumcision and HIV prevention: policy and programme implications. WHO/UNAIDS technical consultation. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS and World Health Organization, 2007.
60. Auvert B, Sobngwi-Tambekou J, Cutler E, et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in orange farm, South Africa. J Infect Dis 2009; 199:14-9.
61. Sobngwi-Tambekou J, Taljaard D, Nieuwoudt M, Lissouba P, Puren A, Auvert B. Male circumcision and Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis: observations in the aftermath of a randomised controlled trial for HIV prevention. Sex Transm Infect 2009; 85:116-20.
62. Tobian AA, Serwadda D, Quinn TC, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009; 360:1298-309.
63. Warner L, Ghanem KG, Newman DR, Macaluso M, Sullivan PS, Erbelding EJ. Male circumcision and risk of HIV infection among heterosexual African American men attending Baltimore sexually transmitted disease clinics. J Infect Dis 2009; 199:59-65.
64. Millett GA, Flores SA, Marks G, Reed JB, Herbst JH. Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis. JAMA 2008; 300: 1674-84.
65. Gust DA, Wiegand RE, Kretsinger K, et al. Circumcision status and HIV infection among MSM: reanalysis of a phase III HIV vaccine clinical trial. AIDS 2010; 24:1135-43.
66. Gray RH, Kigozi G, Serwadda D, et al. The effects of male circumcision on female partners' genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda. Am J Obstet Gynecol 2009; 200:42 e1-7.
67. Padian NS, Buve A, Balkus J, Serwadda D, Cates W Jr. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet 2008; 372:585-99.
68. Cates W, Feldblum P. HIV prevention research: the ecstasy and the agony. Lancet 2008; 372:1932-3.
69. Abdool Karim SS, Richardson BA, Ramjee G, et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 2011; 25:957-66.
70. Rotheram-Borus MJ, Koopman C. Sexual risk behavior, AIDS knowledge, and beliefs about AIDS among predominantly minority gay and bisexual male adolescents. AIDS Educ Prev 1991; 3:305-12.
71. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1977-87.
72. Austin MN, Rabe LK, Hillier SL. Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis 2009; 36:368-71.
73. Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008; 359:463-72.
74. Halpern V, Ogunsola F, Obunge O, et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One 2008; 3:e3784.
75. Peterson L, Nanda K, Opoku BK, et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One 2007; 2:e1312.
76. Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008; 3:e1474.
77. Padian NS, van der Straten A, Ramjee G, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet 2007; 370:251-61. (Pubitemid 47069513)
78. Ramjee G, van der Straten A, Chipato T, et al. The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial. PLoS One 2008; 3:e3488.
79. Sawaya GF, Chirenje MZ, Magure MT, et al. Effect of diaphragm and lubricant gel provision on human papillomavirus infection among women provided with condoms: a randomized controlled trial. Obstet Gynecol 2008; 112:990-7.
80. Phillips DM, Sudol KM, Taylor CL, Guichard L, Elsen R, Maguire RA. Lubricants containing N-9 may enhance rectal transmission of HIV and other STIs. Contraception 2004; 70:107-10. (Pubitemid 38993485)
81. McGowan I. Rectal microbicides: a new focus for HIV prevention. Sex Transm Infect 2008; 84:413-7.
82. Heffron R, Donnell D, Rees H, et al. Hormonal contraceptive use and risk of HIV-1 transmission: a prospective cohort analysis [abstractWEAZ0206]. In: Sixth IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 2011.
83. Morrison CS, Richardson BA, Mmiro F, et al. Hormonal contraception and the risk of HIV acquisition. AIDS 2007; 21:85-95. (Pubitemid 44912541)
84. Morrison CS, Chen PL, Kwok C, et al. Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS 2010; 24:1778-81.
85. Baeten JM, Benki S, Chohan V, et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS 2007; 21:1771-7. (Pubitemid 47237565)
86. Mohllajee AP, Curtis KM, Martins SL, Peterson HB. Hormonal contraceptive use and risk of sexually transmitted infections: a systematic review. Contraception 2006; 73:154-65. (Pubitemid 43087765)
87. Overton ET, Shacham E, Singhatiraj E, Nurutdinova D. Incidence of sexually transmitted infections among HIV-infected women using depot medroxyprogesterone acetate contraception. Contraception 2008; 78:125-30.
88. Low N, Chersich MF, Schmidlin K, et al. Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. PLoS Med 2011; 8:e1000416.
89. Hassan WM, Lavreys L, Chohan V, et al. Associations between intravaginal practices and bacterial vaginosis in Kenyan female sex workers without symptoms of vaginal infections. Sex Transm Dis 2007; 34:384-8. (Pubitemid 46816785)
90. Myer L, Kuhn L, Stein ZA, Wright TC Jr, Denny L. Intravaginal practices, bacterial vaginosis, and women's susceptibility to HIV infection: epidemiological evidence and biological mechanisms. Lancet Infect Dis 2005; 5:786-94. (Pubitemid 41688983)
91. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. New Engl J Med 2008; 359:119-29. (Pubitemid 351962035)
92. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New Engl J Med 2011; 365:493-505.
93. Anglemyer A, Rutherford GW, Egger M, Siegfried N. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev 2011; 93:1-47.
94. Cohen MS, Kashuba AD. Antiretroviral therapy for prevention of HIV infection: new clues from an animal model. PLoS Med 2008; 5:e30.
95. Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, doubleblind, randomized, placebo-controlled trial. PLoS Clin Trials 2007; 2:e27.
96. Karim QA, Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 10:1126.
97. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99.
98. Grant R, Lama JR, Glidden DV. Team iS. Pre-exposure chemoprophylaxis for prevention of HIV among trans-women and MSM: iPrEx Study. In: Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2011.
99. Liu AY, Vittinghoff E, Irby R, et al. BMD loss in HIV-men participating in a TDF PrEP clinical trial in San Francisco. In: Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2011.
100. Centers for Disease Control and Prevention. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 2011; 60:65-8.
101. Baeten JM. for the Partners in Prevention HSV/HIV Transmission Study Team. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study. In: Sixth IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 2011.
102. Thigpen MC, Kebaabetswe PM, Smith D, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. In: Sixth IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 2011.
103. FHI statement on the FEM-PrEP HIV preventions study. 2011. Available at: http://www.fhi.org/en/AboutFHI/Media/Releases/FEMPrEP-statement041811.htm. Accessed 18 April 2011.
104. Abu-Raddad LJ, Magaret AS, Celum C, et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One 2008; 3:e2230.
105. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73-83. (Pubitemid 41818117)
106. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:2109-19. (Pubitemid 351902179)
107. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358:1560-71. (Pubitemid 351519816)
108. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362:427-39.
109. Lingappa JR, Baeten JM, Wald A, et al. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 2010; 375:824-33.
110. Karim QA, Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. In: 18th International AIDS Conference. Vienna, Austria, 2010.
111. McClelland RS, Richardson BA, Hassan WM, et al. Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis 2008; 197:1361-8. (Pubitemid 351706458)
112. Schwebke JR, Desmond R. A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J Obstet Gynecol 2007; 196:517 e1-6.
113. Cheng L, Gulmezoglu AM, Piaggio G, Ezcurra E, van Look PF. Interventions for emergency contraception. Update of 2004 document. Cochrane Database Syst Rev 2008; 16:CD001324.
114. Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FS, Kowal D. Contraceptive Technology. 19th ed. New York: Ardent Media, 2007.
115. Stewart FS, Trussell J, van Look PF. Emergency contraception. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FS, Kowal D, eds. Contraceptive technology. 19th ed. New York, NY: Ardent Media, 2007; 87-116.
116. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. MMWR Recomm Rep 2005; 54:1-20.
117. Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines. MMWR Recomm Rep 2010; 59:1-110.
118. US Preventive Services Task Force. Behavioral counseling to prevent sexually transmitted infections: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 491-6, W95.
119. Lin JS, Whitlock E, O'Connor E, Bauer V. Behavioral counseling to prevent sexually transmitted infections: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: 497-508, W96-9.
120. Centers for Disease Control and Prevention; Health Resources and Services Administration; National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America; HIV Prevention in Clinical Care Working Group. Recommendations for incorporating human immunodeficiency virus (HIV) prevention into the medical care of persons living with HIV. Clin Infect Dis 2004; 38:104-21.
121. McClelland RS, Baeten JM. Reducing HIV-1 transmission through prevention strategies targeting HIV-1-seropositive individuals. J Antimicrob Chemother 2006; 57:163-6. (Pubitemid 43160153)
122. Dunne EF, Chapin JB, Rietmeijer CA, et al. Rate and predictors of repeat Chlamydia trachomatis infection among men. Sex Transm Dis 2008; 35:S40-4.
123. Gaydos CA, Wright C, Wood BJ, Waterfield G, Hobson S, Quinn TC. Chlamydia trachomatis reinfection rates among female adolescents seeking rescreening in school-based health centers. Sex Transm Dis 2008; 35:233-7. (Pubitemid 351619517)
124. Peterman TA, Tian LH, Metcalf CA, et al. High incidence of new sexually transmitted infections in the year following a sexually transmitted infection: a case for rescreening. Ann Intern Med 2006; 145:564-72. (Pubitemid 46780935)